DRUG · Mapped RxNorm record
Trametinib
Normalized identity: trametinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
NCT04967079
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Anlotinib
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTrametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
TrametinibDRUG · verified · RxNorm: trametinib
AnlotinibDRUG
Sponsors & collaborators
Shanghai Chest Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04967079 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.